.png)
Oncology Updates - Key Oncology News
- Oncofocus Team
- Apr 1
- 2 min read
March 4th Week, 2026
Regulatory Events
🎯 The US FDA granted approval to Corcept Therapeutics Incorporated's relacorilant (selective glucocorticoid receptor antagonist) + nab-paclitaxel for the treatment of adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatment regimens, at least one of which included bevacizumab. (Ref 1)
❓ What are the clinical outcomes that support this approval?
🎯 Japan’s Ministry of Health, Labour and Welfare (MHLW) granted approval to AstraZeneca & Daiichi Sankyo US' trastuzumab deruxtecan (HER2 ADC) for the treatment of adult patients with HER2+, advanced or recurrent solid cancers refractory or intolerant to standard treatments. (Ref 2)
❓ How is Enhertu positioned in Japan’s solid tumor market landscape?
Special Designations
⭐ The US FDA granted the fast track designation to TRIANA Biomedicines' TRI-611 (molecular glue degrader therapy) for the treatment of ALK+ NSCLC. (Ref 3)
❓ What are the key unmet medical needs of this indication?
⭐ The US FDA granted the orphan drug designation to ReCerise Therapeutics' RCT1213 (anti-TM4SF5) for hepatocellular carcinoma (HCC). (Ref 4)
❓ Which are the key promising assets in the HCC landscape?
Clinical Events
🔬 Karyopharm Therapeutics Inc. reported topline results from its Phase 3 SENTRY trial of selinexor 60 mg + ruxolitinib in frontline myelofibrosis. (Ref 5)
❓ What are the current efficacy and safety benchmarks for frontline myelofibrosis Tx?
Deals And Collaborations
🤝 Merck & Co./MSD and Terns Pharmaceuticals entered into a definitive agreement under which Merck will acquire Terns for $53.00 per share in cash for an approximate equity value of $6.7 billion (Ref 6)
❓ Who are the key competitors to Terns Pharma’s lead candidate, TERN-701?
To know answers to these questions and for additional insights, write to us at support@oncofocus.com.
🌐 References:
Comments